Discover and read the best of Twitter Threads about #ColorectalCancer
Most recents (20)
@TumorBoardTues @JohnEbbenMDPhD #TumorBoardTuesday
📣Welcome as we summarize some of the incredible data from #ASCO23
👉There was SO much to take in, that even focusing on GI Cancers was a challenge
🙏As always, these were the🧑🏫that caught OUR interest, but this is not a judgement on those we do not highlight‼️
📣Welcome as we summarize some of the incredible data from #ASCO23
👉There was SO much to take in, that even focusing on GI Cancers was a challenge
🙏As always, these were the🧑🏫that caught OUR interest, but this is not a judgement on those we do not highlight‼️
@TumorBoardTues @JohnEbbenMDPhD 1/21
#TumorBoardTuesday
🤔Speaking for myself, @knutjla ‘s data has shaken my practice the most (including twice last week)
👉He presented the NORPACT-1 trial of peri-operative FOLFIRINOX vs. upfront🔪for resectable #PancreaticCancer
#TumorBoardTuesday
🤔Speaking for myself, @knutjla ‘s data has shaken my practice the most (including twice last week)
👉He presented the NORPACT-1 trial of peri-operative FOLFIRINOX vs. upfront🔪for resectable #PancreaticCancer
@TumorBoardTues @JohnEbbenMDPhD @knutjla @MDAkhilChawla @FlavioRochaMD @NbmerchantMD @MadameSurgeon @NirajGusani @TsengJennifer 2/21
#TumorBoardTuesday
✅@knutjla🗣️a well designed, well run trial
✅The authors even hypothesized a 20%⬆️in mOS
➡️However, pre-operative chemotherapy led to a significant⬇️in 18 month mOS😲
👉Despite a much better R0 resection rate
🤔What are your thoughts💭❓
#TumorBoardTuesday
✅@knutjla🗣️a well designed, well run trial
✅The authors even hypothesized a 20%⬆️in mOS
➡️However, pre-operative chemotherapy led to a significant⬇️in 18 month mOS😲
👉Despite a much better R0 resection rate
🤔What are your thoughts💭❓
Metastatic #ColorectalCancer is treated with fluorouracil-based combination chemotherapy with oxaliplatin, with or without irinotecan.
Read the Science behind the Study: nej.md/3VnWj8L 1/15
Read the Science behind the Study: nej.md/3VnWj8L 1/15
Inhibitors of vascular endothelial growth factor (VEGF), such as bevacizumab, or epidermal growth factor receptor (EGFR) (for patients without activating RAS variants) are sometimes also included. 2/15
Patients with treatment-refractory disease who have progression after these therapies have limited treatment options, outside of clinical trials. 3/15
😀I am so excited to be at my 1⃣st IN PERSON ASCO GI in 3y
✅To prepare, I have gone through the abstract titles, and here are my Top GI ASCO 2023 abstracts
📣Disclaimer: There is no bias or exclusion intended.
These are just the ones I personally want to see👀
✅To prepare, I have gone through the abstract titles, and here are my Top GI ASCO 2023 abstracts
📣Disclaimer: There is no bias or exclusion intended.
These are just the ones I personally want to see👀
#GI23
➡️Starting with #Cholangiocarcinoma because it is a big year - especially because of:
✅SWOG 1815: A phase III trial of gem-cis-nab-pac vs. gem-cis as 1⃣st line💊for advanced BTC
👁️Rachna Shroff, Abs LBA490
@rachnatshroff
➡️Starting with #Cholangiocarcinoma because it is a big year - especially because of:
✅SWOG 1815: A phase III trial of gem-cis-nab-pac vs. gem-cis as 1⃣st line💊for advanced BTC
👁️Rachna Shroff, Abs LBA490
@rachnatshroff
#GI23
➡️Two impt ImmunoTx trials:
✅IMbrave151: Phase 2 trial of gem-cis-atezo + /- bev as 1⃣st line💊for advanced BTC
👁️A El-Khoueiry, Abs 491
✅Also a TOPAZ-1 report on the long-term survivors Txed with gem-cis-durva 1⃣st line for advanced BTC
👁️M Bouattour, Abs 531, Pos C1
➡️Two impt ImmunoTx trials:
✅IMbrave151: Phase 2 trial of gem-cis-atezo + /- bev as 1⃣st line💊for advanced BTC
👁️A El-Khoueiry, Abs 491
✅Also a TOPAZ-1 report on the long-term survivors Txed with gem-cis-durva 1⃣st line for advanced BTC
👁️M Bouattour, Abs 531, Pos C1
A #Colonoscopy #Tweetorial: (1/10)
⭐️To make yours go well
⭐️To ACE the prep
Background:
👉🏼50 yrs: Past start CRC screening
👉🏼45 yrs: New start for average risk
tinyurl.com/y7u98crs
💠Just had first colonoscopy
💠Yeah, I know. Give grace!
My 1st time tips as a GI doc!
⭐️To make yours go well
⭐️To ACE the prep
Background:
👉🏼50 yrs: Past start CRC screening
👉🏼45 yrs: New start for average risk
tinyurl.com/y7u98crs
💠Just had first colonoscopy
💠Yeah, I know. Give grace!
My 1st time tips as a GI doc!
Colonoscopy requires planning! (2/10)
📅 Plan a date in advance
📅 Ensure you will have a driver
📅 Be sure you pick up the prep
📅 Read instructions a week before
📅 Don’t make plans night before!
📅 Don’t make plans the night of!
#ColorectalCancer
#ColorectalCancerAwareness
📅 Plan a date in advance
📅 Ensure you will have a driver
📅 Be sure you pick up the prep
📅 Read instructions a week before
📅 Don’t make plans night before!
📅 Don’t make plans the night of!
#ColorectalCancer
#ColorectalCancerAwareness
Colonoscopy requires shopping! (3/10)
👉🏼Need clear liquids 24 hrs+
(longer if bad preps)
Stock up:
🥤Juice (apple/white grape)
🥤Non-fatty broth
🥤Jello, popsicles (no red)
🥤Sports drinks
🥤Coffee, tea
*also wet wipes* (later)
A “fav” of mine:
👉🏼Bone broth w/protein
👉🏼Need clear liquids 24 hrs+
(longer if bad preps)
Stock up:
🥤Juice (apple/white grape)
🥤Non-fatty broth
🥤Jello, popsicles (no red)
🥤Sports drinks
🥤Coffee, tea
*also wet wipes* (later)
A “fav” of mine:
👉🏼Bone broth w/protein
An article describing the "45 is the new 50" change in guidelines in the US for #ColorectalCancer #Screening. Slightly biased towards $EXAS Exact Sciences Cologuard. ache.org/blog/2022/upda…
$EXAS Exact Sciences is one of the companies I track, in many ways a pioneer in the #LiquidBiopsy #CancerScreening field although with a low-tech method compared to other players in this field such as $ILMN Illumina (via @GrailBio), and what other companies are planning ...
Yesterday at #TargetedChat we talked about a challenging case of a young individual with recurrent UNRESECTABLE colon cancer after adjuvant.
Here’s a 🧵 on the questions/answers. No one right away. What would you do differently?👇🏾Read/reply along #ColorectalCancerAwarenessMonth
Here’s a 🧵 on the questions/answers. No one right away. What would you do differently?👇🏾Read/reply along #ColorectalCancerAwarenessMonth
It was interesting to see the distribution on the chemo backbone options.
TRIPLETS 🆚 DOUBLETS #TargetedChat #CRCSM
TRIPLETS 🆚 DOUBLETS #TargetedChat #CRCSM
👇🏾With the doublets and triplets discussion, a little bit of art 🖼 to the science 🧪
Have to see and individualize in each patient which tools 🛠 from the toolbox 🧰.
#TargetedChat #CRCSM #ColorectalCancer #ColorectalCancerAwarenessMonth
Have to see and individualize in each patient which tools 🛠 from the toolbox 🧰.
#TargetedChat #CRCSM #ColorectalCancer #ColorectalCancerAwarenessMonth
HBD to ABGH! 🥳
Today marks ABGH's 1st bday and we are OUT HERE!
We're so proud of all this org's done in year one, & all it strives to achieve as we grow TOGETHER. We're grateful to our members, sponsors, & allies!
Go to blackingastro.org to learn more.
#blackingastro
Today marks ABGH's 1st bday and we are OUT HERE!
We're so proud of all this org's done in year one, & all it strives to achieve as we grow TOGETHER. We're grateful to our members, sponsors, & allies!
Go to blackingastro.org to learn more.
#blackingastro
Interested in what's in store for ABGH in early 2022?
Members! Check your 📨 (*and spam!*) to sign up for our ABGH Masterclass Series: Financial Literacy 101.
Trevor Rozier Byrd, founder/CEO of @StackwellCap, will be our guest speaker. A MUST ATTEND members only event!
Members! Check your 📨 (*and spam!*) to sign up for our ABGH Masterclass Series: Financial Literacy 101.
Trevor Rozier Byrd, founder/CEO of @StackwellCap, will be our guest speaker. A MUST ATTEND members only event!
And for ABGH's 2nd annual virtual #ColorectalCancerAwarenessMonth event open to the public, we're excited to partner with @FightCRC & @NCCRTnews!
Let's Beat #ColorectalCancer: An Update for the Black Community
When: March 10, 8-9PM ET
RSVP: letsbeatcrc.eventbrite.com
#blackingastro
Let's Beat #ColorectalCancer: An Update for the Black Community
When: March 10, 8-9PM ET
RSVP: letsbeatcrc.eventbrite.com
#blackingastro
1/ Why automated quality metrics may be the key to unlocking adoption of new polyp detection technologies for #colorectalcancer screening, a brief 🧵
2/ A common refrain is that cost barriers have been the central reason for slow uptake of evidence-based polyp detection technologies (mucosal exposure caps, wide angle colo, & perhaps #AI).
3/ I think that's not the whole story. This pattern also exposes the near absence of user-friendly, automated endoscopy quality analytics tools.
Good Morning #GImedTwitter
🌅🌄🌇Whether you are waking up in San Francisco…..or not (Curse you COVID-19😡)
🧑🏫Get ready for 3 packed days of presentations at #GI22
And to get the🧠started, we are going to share our
Top 10 Targeted Therapy Abstracts🎯
#TumorBoardTuesday
🌅🌄🌇Whether you are waking up in San Francisco…..or not (Curse you COVID-19😡)
🧑🏫Get ready for 3 packed days of presentations at #GI22
And to get the🧠started, we are going to share our
Top 10 Targeted Therapy Abstracts🎯
#TumorBoardTuesday
#TumorBoardTuesday
1⃣/
Once again HER2🎯💊is everywhere #GI22
👉The DESTINY trials have been👍4⃣T-DXd
✅DESTINY-CRC01
➡️T Yoshino, et al "RAPID" Abs 119
⏩53 "Group A" HER2+ RASWT CRC pts
⏩ORR 45%, mOS 15.5 mos
👍Even with prior HER2 Tx
😨But GR>=3 AEs in 65% of pts, 9% ILD
1⃣/
Once again HER2🎯💊is everywhere #GI22
👉The DESTINY trials have been👍4⃣T-DXd
✅DESTINY-CRC01
➡️T Yoshino, et al "RAPID" Abs 119
⏩53 "Group A" HER2+ RASWT CRC pts
⏩ORR 45%, mOS 15.5 mos
👍Even with prior HER2 Tx
😨But GR>=3 AEs in 65% of pts, 9% ILD
#TumorBoardTuesday #GI22
2⃣/
✅DESTINY-Gastric 01
➡️K Yamaguchi, et al "RAPID" Abs 242
⏩Randomized Ph II trial of >=2nd line💊
👉T-DXd vs. Physician’s choice (PC) which was Iri or Paclitaxel
⏩mOS 12.5 v 8.9 mos
⏩ORR 51% vs 14%
😨But Grade >= 3 AEs were 86% vs 57%
2⃣/
✅DESTINY-Gastric 01
➡️K Yamaguchi, et al "RAPID" Abs 242
⏩Randomized Ph II trial of >=2nd line💊
👉T-DXd vs. Physician’s choice (PC) which was Iri or Paclitaxel
⏩mOS 12.5 v 8.9 mos
⏩ORR 51% vs 14%
😨But Grade >= 3 AEs were 86% vs 57%
Pls join us in welcoming @JohnEbbenMDPhD to #TumorBoardTuesday!! 🎊
Dr Ebben is an onc fellow from WI, interested in🧬med & immunotherapy. He’ll also debate🧀curds & the best🍦custard in WI! He’ll be assisting with case wrap up🎀
We’re excited to have him!! #TBTFellow 1/17
Dr Ebben is an onc fellow from WI, interested in🧬med & immunotherapy. He’ll also debate🧀curds & the best🍦custard in WI! He’ll be assisting with case wrap up🎀
We’re excited to have him!! #TBTFellow 1/17
2/17 #TumorBoardTuesday Thursday Case🎀(08/24/21)
Bringing #ctDNA to bear to improve pts🙌🏽 @pashtoonkasi shows us how we can♻️ 🎯therapies to extend survival.
We go deep -🔬molecular biology➡️clinical trials➡️pt case.
👉🏽Don’t forget🆓#CME credit: bit.ly/3B9i6Wd
Bringing #ctDNA to bear to improve pts🙌🏽 @pashtoonkasi shows us how we can♻️ 🎯therapies to extend survival.
We go deep -🔬molecular biology➡️clinical trials➡️pt case.
👉🏽Don’t forget🆓#CME credit: bit.ly/3B9i6Wd
3/17 #TumorBoardTuesday Thursday Case🎀(08/24/21)
📚We captured as much of @pashtoonkasi's discussion as we could in this moment:
#ColorectalCancer #CRC #OncTwitter
twitter.com/i/events/14288…
📚We captured as much of @pashtoonkasi's discussion as we could in this moment:
#ColorectalCancer #CRC #OncTwitter
twitter.com/i/events/14288…
@ShimaghavimiMD @TumorBoardTues #TumorBoardTuesday
Case 08/03/21
74 yo♂️presents with RUQ pain and fatigue, 30# weight loss, PS=2
CT scan demonstrates a large panc mass and diffuse liver metastases
Liver core biopsy confirms an acinar cell #PancreaticCancer
➡️What would be your treatment recommendation❓
Case 08/03/21
74 yo♂️presents with RUQ pain and fatigue, 30# weight loss, PS=2
CT scan demonstrates a large panc mass and diffuse liver metastases
Liver core biopsy confirms an acinar cell #PancreaticCancer
➡️What would be your treatment recommendation❓
@ShimaghavimiMD @TumorBoardTues #TumorBoardTuesday
08/03/21
He was treated with every other week Gem-nab-pac
🙏@GIcancerDoc
➡️Had rapid symptomatic improvement
➡️Now essentially normal PS
➡️Nice response to treatment for 9 months🙂
But then disease progression❗️
What would be your 2nd line therapy choice❓
08/03/21
He was treated with every other week Gem-nab-pac
🙏@GIcancerDoc
➡️Had rapid symptomatic improvement
➡️Now essentially normal PS
➡️Nice response to treatment for 9 months🙂
But then disease progression❗️
What would be your 2nd line therapy choice❓
@ShimaghavimiMD @TumorBoardTues @GIcancerDoc #TumorBoardTuesday
08/03/21
Germline NGS🧬testing did not reveal any inherited alterations
☝️Somatic (tumor) NGS🧬testing revealed a
💥BRAFV600E mutation💥
✅And no KRAS mutation
➡️Done while on 1st line therapy
Would the results alter your treatment choice now?
08/03/21
Germline NGS🧬testing did not reveal any inherited alterations
☝️Somatic (tumor) NGS🧬testing revealed a
💥BRAFV600E mutation💥
✅And no KRAS mutation
➡️Done while on 1st line therapy
Would the results alter your treatment choice now?
#TumorBoardTuesday
THANK YOU to @KristenCiombor for leading us through a🗣️on pMMR CRC w/ dMMR liver mets
AND thank you for @fireflyann for leading our #PatientExperience 🗣️as well
👉Don’t forget your🆓#CME credit-answer 3 quick❓
Here's the postest🔗
surveymonkey.com/r/DMN786G
THANK YOU to @KristenCiombor for leading us through a🗣️on pMMR CRC w/ dMMR liver mets
AND thank you for @fireflyann for leading our #PatientExperience 🗣️as well
👉Don’t forget your🆓#CME credit-answer 3 quick❓
Here's the postest🔗
surveymonkey.com/r/DMN786G
#TumorBoardTuesday
Thursday Case🎀(Reverse jet-lag edition✈️)
(07/06 and 07/07/21)
We🗣️ #ColorectalCancer and:
✅1st line Tx for dMMR met CRC
✅✔️ing MMR status EVEN in patients with Lynch Syndrome
✅Tumor heterogeneity
We captured the🗣️in this moment:
twitter.com/i/events/14131…
Thursday Case🎀(Reverse jet-lag edition✈️)
(07/06 and 07/07/21)
We🗣️ #ColorectalCancer and:
✅1st line Tx for dMMR met CRC
✅✔️ing MMR status EVEN in patients with Lynch Syndrome
✅Tumor heterogeneity
We captured the🗣️in this moment:
twitter.com/i/events/14131…
#TumorBoardTuesday
Thursday Case🎀
(From 07/06 and 07/07/21)
In the #PatientExperience 🗣️we added:
✅Defining the "lingo", e.g.
👉dMMR = MSI-high
👉pMMR = MS-stable
✅Ensuring tumor testing - and🗣️results w/ docs
✅Scanxiety
Also captured in this moment:
twitter.com/i/events/14132…
Thursday Case🎀
(From 07/06 and 07/07/21)
In the #PatientExperience 🗣️we added:
✅Defining the "lingo", e.g.
👉dMMR = MSI-high
👉pMMR = MS-stable
✅Ensuring tumor testing - and🗣️results w/ docs
✅Scanxiety
Also captured in this moment:
twitter.com/i/events/14132…
Gather around with a snack and ☕️!! We’ll begin with @fireflyann in ≈ 30mins!!
Please share and invite other members of the cancer community!
#TumorBoardTuesday #PatientExperience #ColorectalCancer @MPishvaian @KristenCiombor @Empoweringpts9
Please share and invite other members of the cancer community!
#TumorBoardTuesday #PatientExperience #ColorectalCancer @MPishvaian @KristenCiombor @Empoweringpts9
A couple of reminders.
If you need medical advice, or questions about your treatment or your personal care, please speak with your in-person care team.
#TumorBoardTuesday #PatientExperience #ColorectalCancer #CRC 1/3 @fireflyann
If you need medical advice, or questions about your treatment or your personal care, please speak with your in-person care team.
#TumorBoardTuesday #PatientExperience #ColorectalCancer #CRC 1/3 @fireflyann
Reminder:
Everyone responds to treatment different, please be mindful of other’s experiences.
#TumorBoardTuesday #PatientExperience #ColorectalCancer @fireflyann 2/3
Everyone responds to treatment different, please be mindful of other’s experiences.
#TumorBoardTuesday #PatientExperience #ColorectalCancer @fireflyann 2/3
#TumorBoardTuesday
🙏for joining &⚖️in on a robust🗣️ with A LOT of deep🔬on NRG-1 fusion+ #CRC led by @benweinbergmd
➡️Here is this week's Thursday Case🎀
👉👉Don't forget to pick up your🆓#CME credit by answering 2 quick❓
Here is the post-test🔗
bit.ly/3fFpTUe
🙏for joining &⚖️in on a robust🗣️ with A LOT of deep🔬on NRG-1 fusion+ #CRC led by @benweinbergmd
➡️Here is this week's Thursday Case🎀
👉👉Don't forget to pick up your🆓#CME credit by answering 2 quick❓
Here is the post-test🔗
bit.ly/3fFpTUe
#TumorBoardTuesday
Thursday Case🎀
(Case from 04/06/21)
We discussed #colorectalcancer and:
✅ChemoTx choices and sequencing
✅5FU cardiotox
✅KRAS and other🧬alterations
✅And of course all about NRG-1
We captured as much as we could in this moment:
twitter.com/i/events/13794…
Thursday Case🎀
(Case from 04/06/21)
We discussed #colorectalcancer and:
✅ChemoTx choices and sequencing
✅5FU cardiotox
✅KRAS and other🧬alterations
✅And of course all about NRG-1
We captured as much as we could in this moment:
twitter.com/i/events/13794…
#TumorBoardTuesday
Thursday Case🎀
(Case from 04/06/21)
@benweinbergmd presented a case of a patient with met #CRC
👍2-dary🗣️on:
➡️What chemo after metastasectomy
➡️💪evidence for FOLFOXIRI+mAb for metCRC
ncbi.nlm.nih.gov/pubmed/17470860
ncbi.nlm.nih.gov/pubmed/16508637
ncbi.nlm.nih.gov/pubmed/26338525
Thursday Case🎀
(Case from 04/06/21)
@benweinbergmd presented a case of a patient with met #CRC
👍2-dary🗣️on:
➡️What chemo after metastasectomy
➡️💪evidence for FOLFOXIRI+mAb for metCRC
ncbi.nlm.nih.gov/pubmed/17470860
ncbi.nlm.nih.gov/pubmed/16508637
ncbi.nlm.nih.gov/pubmed/26338525
#ColorectalCancerAwarenessMonth ⭐️
@renehan_andrew & his team have produced world-leading research on #ColorectalCancer, involving the link to obesity & the investigation of organ preservation to avoid rectal cancer surgery.
Read about his team & their projects below 👇
[1/9]
@renehan_andrew & his team have produced world-leading research on #ColorectalCancer, involving the link to obesity & the investigation of organ preservation to avoid rectal cancer surgery.
Read about his team & their projects below 👇
[1/9]
Meet @NadinHawwash, a medical student intercalating on the new MB-PhD programme!
Nadin's research is part of the ABACus2 project, which is investigating the life-course exposure to body fatness & the related cancer risk!
Read about this project 👇
abacus-study.co.uk/abacus2/
[2/9]
Nadin's research is part of the ABACus2 project, which is investigating the life-course exposure to body fatness & the related cancer risk!
Read about this project 👇
abacus-study.co.uk/abacus2/
[2/9]
1/3 of high-risk rectal cancer patients will receive chemotherapy & surgery - the latter leading to co-morbidities.
@LeeMalcomson works on OnCoRe, a database which identifies non-surgery treatment alternatives such as a Watch-&-Wait strategy 👇
complete-response.com
[3/9]
@LeeMalcomson works on OnCoRe, a database which identifies non-surgery treatment alternatives such as a Watch-&-Wait strategy 👇
complete-response.com
[3/9]
#fromGENEtoSCREEN #colorectalcancer #GITwitter
This will be the first of many tweetorials regarding colorectal cancer, focused on prevention.
We will try to understand and interrelate as many concepts as possible.
Feel free to add, discuss, correct, and even troll 🤣
This will be the first of many tweetorials regarding colorectal cancer, focused on prevention.
We will try to understand and interrelate as many concepts as possible.
Feel free to add, discuss, correct, and even troll 🤣
EPISODE 1
Colonic histology:
The colon is composed of the four layers characteristic of the gastrointestinal tract. Mucosa, submucosa, muscularis propria and serosa
Colonic histology:
The colon is composed of the four layers characteristic of the gastrointestinal tract. Mucosa, submucosa, muscularis propria and serosa
The MUCOSA consists of two types of cells: absorptive cells and mucus-secreting goblet cells. These are arranged in closely packed straight tubular glands or crypts (of Lieberkuhn), which extend to the muscularis mucosa. Lamina Propria: abundant between cross-sections of...
Thank you @BilalMohammadMD @AmyOxentenkoMD for reigniting a convo ab #medtwitter #GITwitter, an important facet of the healthcare #SoMe landscape.
Let's review a few analyses we performed over the years on engagement + impact of GI #SoMe:
(Evidence to convince more to join?)
🧵
Let's review a few analyses we performed over the years on engagement + impact of GI #SoMe:
(Evidence to convince more to join?)
🧵
Q: Is there benefit to divisional social media presence for a healthcare dept/institution?
With @DrLorenGR @walterchanMD we demonstrated an ⬆️ in institutional social media presence predicted GI divisional #ranking improvement on @USNewsHealth
jmir.org/2019/9/e13345/ @jmirpub
With @DrLorenGR @walterchanMD we demonstrated an ⬆️ in institutional social media presence predicted GI divisional #ranking improvement on @USNewsHealth
jmir.org/2019/9/e13345/ @jmirpub
As mentioned, with @BrennanSpiegel @Doctor_V we created the GI hashtag ontology in 2016 to standardize GI discourse on Twitter with all GI societies/journals at the time, after a discussion w @subatomicdoc whose work in Heme/Onc inspired us. @symplur
journals.lww.com/ajg/Citation/2…
journals.lww.com/ajg/Citation/2…
Bird’s-eye view 👁 on what to look out for @WCGIC #WorldGI2020.
Opening remarks on important data 📺 @myESMO - by Dr. Eric Van Cutsem @UZLeuven.
🟩Good to see more #PrecisionMedicine🧬
🟥#Immunotherapy #Immuno-#oncology
🟦TNT & other chemo strategies
@Annals_Oncology #OncoAlert
Opening remarks on important data 📺 @myESMO - by Dr. Eric Van Cutsem @UZLeuven.
🟩Good to see more #PrecisionMedicine🧬
🟥#Immunotherapy #Immuno-#oncology
🟦TNT & other chemo strategies
@Annals_Oncology #OncoAlert
🆕#ctDNA #liquidbiopsies 🩸🧬
👀 👇🏾at the number of #clinicaltrials cropping up in this space‼️
🇦🇺DYNAMIC-II
🇦🇺DYNAMIC-III
🇺🇸COBRA @NRGonc
🇺🇸BESPOKE
🇺🇸@SU2C
🇯🇵 CIRCULATE
🌎COLUMBIA
🇮🇹🇪🇸PEGASYS
🇬🇧TRACC
🇩🇪CIRCULATE
🇫🇷crEATE
🇩🇰IMPROVE-IT
We have 2🇺🇸studies open. #CRCSM #WorldGI2020
👀 👇🏾at the number of #clinicaltrials cropping up in this space‼️
🇦🇺DYNAMIC-II
🇦🇺DYNAMIC-III
🇺🇸COBRA @NRGonc
🇺🇸BESPOKE
🇺🇸@SU2C
🇯🇵 CIRCULATE
🌎COLUMBIA
🇮🇹🇪🇸PEGASYS
🇬🇧TRACC
🇩🇪CIRCULATE
🇫🇷crEATE
🇩🇰IMPROVE-IT
We have 2🇺🇸studies open. #CRCSM #WorldGI2020
#WORLDGI2020 This is 🆒 ☢️ 32-P EUS-guided implantation in #pancreascancer #PANCSM @myESMO @WCGIC @Annals_Oncology.
Still miles to go. OS median of 16 months pointing again to the systemic nature of disease. Need to piggyback these local approaches to better systemic. #OncoAlert
Still miles to go. OS median of 16 months pointing again to the systemic nature of disease. Need to piggyback these local approaches to better systemic. #OncoAlert
1/9 Quick synopsis of our recent double-blind randomized study on computer-aided polyp detection in @LancetGastroHep, which can be found here: thelancet.com/journals/langa…
2/9 Previous work by our team and others have shown that #AI polyp detection can improve ADR. A major question has been whether use of on-screen computer-aided detection merely increases the vigilance of the endoscopist (vs. specifically helping find more polyps).
3/9 We enrolled 1046 pts. We tried to address operational bias by blinding the endoscopist to whether or not CADe was being used. Blinding is hard. This required development of a 'sham' CADe system by @WisionAI that alerted only to 'polyp-like' findings (bubbles, folds etc).
In this thread, I will compile my medical illustrations in oncology and #RadOnc.
Many are from textbook w @DanTrifMD
amazon.com/Absolute-Clini…
based on @ARRO_org study guide for board exams.
A picture is worth 1000 words.
Here is oncology in a few pics.
Many are from textbook w @DanTrifMD
amazon.com/Absolute-Clini…
based on @ARRO_org study guide for board exams.
A picture is worth 1000 words.
Here is oncology in a few pics.
@DanTrifMD @ARRO_org @SpringerNature Starting with pediatrics:
Rhabdomyosarcoma treatment paradigm for cancers of head/neck depends on parameningeal vs non-parameningeal location. PM is an unfavorable site, affects stage. #sarcoma #HNCSM
Rhabdomyosarcoma treatment paradigm for cancers of head/neck depends on parameningeal vs non-parameningeal location. PM is an unfavorable site, affects stage. #sarcoma #HNCSM
@DanTrifMD @ARRO_org @SpringerNature CNS/brain anatomy from sagittal view.
#BTSM
Chapter from @cgr0105, Sameer Nath, from University of Colorado
#BTSM
Chapter from @cgr0105, Sameer Nath, from University of Colorado
